Our work bridges the gap between association studies of common variants and sequencing studies of rare variants by simultaneously assessing both rare and common variation. The approximately 500,000 markers included on the consortium’s array, along with the more than 11 million subsequently imputed variants, provide superior coverage of known disease susceptibility loci through intentional fine-mapping and improve the power for novel disease locus detection, as this is the largest genomic analysis of AMD to date.
These data support the consortium’s analysis of the genetic architecture of AMD, including more detailed analyses of genes, interactions, pathways, and phenotypes.